MedPath

Utilization of Platelet Gel for Treatment of Diabetic Foot Ulcers

Phase 1
Completed
Conditions
Diabetic Foot Ulcers
Interventions
Biological: Platelet Gel
Other: Placebo
Registration Number
NCT02134132
Lead Sponsor
Royan Institute
Brief Summary

Diabetes is a multiorgan disease and considered a major health problem in different societies. One of the complications the pain particularly in the extremities resulting from a process known as diabetic foot ulcer. The diabetic patients are subjected to many complications because of foot ulcers, many of them like as chronic wound disease or pressure ulcers (bed sore). Routinely used medical measures for diabetic foot ulcers are depended to nursing care and take too long until pain relief. Among many tested materials and works for wound healing such as debridement, tissue oxygenation, and skin transplantation, platelet-derived compounds are allocated the pivotal position between investigators to tissue regeneration and shortening the wound healing process.

Many of platelet components are procured from platelet rich plasma (PRP) from whole blood donation. Furthermore, it requires to an additional purification step to diminish the volume and facilitate handling in some studies. It means that platelet concentrates (PCs) may be obtained leading to more concentrated platelets in lower volume.

Two types of granules in platelet is responsible for storage of many useful and different growth factors: dense or delta and alpha granules. Platelet-derived growth factors have the ability to growth and differentiation of numerous cells. Also, the antibacterial effect of these growth factors has been reported.

To better efficacy and comfortable utilization of platelet, it is feasible to form the platelet gel and then apply on wound sites.

This study is a double blind randomized controlled trial to evaluate the positive effects of umbilical cord blood-derived platelet gel in 244 patients with diabetic foot ulcers.

Detailed Description

In this study all qualified patients (based on the inclusion and exclusion criteria) were randomly allocated into three study groups by a Stratified Permuted Block randomization method: group A received platelet rich plasma gel, group B (placebo) received platelet poor plasma gel, and group C received lubricant gel.

All of the patients underwent a standard long protocol for knee osteoarthritis. All patients with diabetic foot ulcer are selected.On average,in each instance, the amount of platelets in the peripheral bloodis4 to6 times the baseline level.

Group A (interventional): application of 20-30mL of gel from platelet rich plasma (PRP) Group B (placebo): application of 20-30mL of gel from platelet poor plasma (PRP) Group C (control): application of 20-30 mL of lubricant gel (used typically for sonography)

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • History of at least 4 weeks hospitalization
  • Uncontrolled diabetes
  • ejection fraction > 30%
Exclusion Criteria
  • mechanical origin for wound
  • history of infectious, systemic diseases, Immune deficiency and coagulation disorders

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
platelet rich plasmaPlatelet GelThe patients with diabetic foot ulcer who receive PG treatment.
PlaceboPlaceboThe patients with diabetic foot ulcer who receive placebo.
Primary Outcome Measures
NameTimeMethod
pain3 months

Evaluation the pain reduction by VAS measurement in patients with peripheral artery Disease.

ABI3 months

Evaluation the Ankle Brakial Index (ABI) in patients 3 months after PG utilization.

Secondary Outcome Measures
NameTimeMethod
Quality of life3months

Evaluation the quality of life by SF36 measurement in patients with PAD.

Trial Locations

Locations (1)

Royan Institute

🇮🇷

Tehran, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath